Sensei Biotherapeutics director reports option holdings
Sensei Biotherapeutics, Inc. director Saira Ramasastry reported existing derivative holdings in the form of employee stock options linked to the company’s common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
3
Rhea-AI Filing Summary
Sensei Biotherapeutics, Inc. director Saira Ramasastry reported existing derivative holdings in the form of employee stock options linked to the company’s common stock. One option covers 5,929 underlying shares at an exercise price of $5.22 per share and expires on May 10, 2034.
A second option covers 8,718 underlying shares at an exercise price of $1.16 per share and expires on January 24, 2036. Footnotes explain these options were received in exchange for prior Faeth-related stock options pursuant to a February 17, 2026 Agreement and Plan of Merger.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Ramasastry Saira
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
Holdings After Transaction:
Employee Stock Option (right to buy) — 14,647 contracts (Direct)
Footnotes (5)
- F1. Beginning August 1, 2022, the shares subject to the option vest in a series of twenty-four (24) successive equal monthly installments.
- F2. Received in exchange for or a stock option to acquire an aggregate 43,739 shares of Faeth Holdings Therapeutics, Inc. ("HoldCo") common stock with an exercise price of $0.23 per share pursuant to an Agreement and Plan of Merger, dated February 17, 2026 (the "Merger Agreement"), by and among the Company, Sapphire First Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Company ("First Merger Sub"), Sapphire Second Merger Sub, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company ("Second Merger Sub"), HoldCo and Faeth Therapeutics, LLC, a Delaware limited liability company and wholly owned subsidiary of HoldCo ("Faeth").
- F3. Under the terms of the Merger Agreement, on February 17, 2026, First Merger Sub merged with and into HoldCo, with HoldCo surviving the first merger as a wholly owned subsidiary of the Company, and immediately following the first merger, HoldCo merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Company (such mergers, the "Merger").
- F4. Fully vested.
- F5. Received in exchange for a stock option to acquire an aggregate 29,746 shares of Faeth common stock with an exercise price of $1.04 per share pursuant to the Merger Agreement.
Key Figures
Option 1 exercise price: $5.22 per share
Option 1 underlying shares: 5,929 shares
Option 2 exercise price: $1.16 per share
+4 more
7 metrics
Option 1 exercise price
$5.22 per share
Employee stock option on 5,929 underlying shares; expires May 10, 2034
Option 1 underlying shares
5,929 shares
Common Stock underlying employee stock option at $5.22 exercise price
Option 2 exercise price
$1.16 per share
Employee stock option on 8,718 underlying shares; expires January 24, 2036
Option 2 underlying shares
8,718 shares
Common Stock underlying employee stock option at $1.16 exercise price
HoldCo option exchange
43,739 shares at $0.23
Faeth Holdings Therapeutics, Inc. HoldCo option exchanged into Sensei option per Merger Agreement
Faeth option exchange
29,746 shares at $1.04
Faeth common stock option exchanged into Sensei option per Merger Agreement
Merger Agreement date
February 17, 2026
Agreement and Plan of Merger governing exchange of Faeth-related options into Sensei options
Key Terms
Employee Stock Option (right to buy), Agreement and Plan of Merger, wholly owned subsidiary, vest, +1 more
5 terms
Employee Stock Option (right to buy) financial
"security_title: Employee Stock Option (right to buy)"
Agreement and Plan of Merger regulatory
"pursuant to an Agreement and Plan of Merger, dated February 17, 2026"
An Agreement and Plan of Merger is a formal document where two companies agree to combine into one, outlining how the process will happen. It’s like a step-by-step plan for merging, and it matters because it shows both sides have agreed on the details before the official transition takes place.
wholly owned subsidiary financial
"with HoldCo surviving the first merger as a wholly owned subsidiary of the Company"
A wholly owned subsidiary is a company whose entire ownership is held by another company (the parent), so the parent controls decisions, operations, and finances. Think of it as a fully controlled branch that runs as its own legal entity but whose results flow straight into the parent’s financial statements; investors watch these structures because they affect consolidated revenue, risk exposure, and how profits, liabilities, and cash flow are allocated across the corporate group.
vest financial
"shares subject to the option vest in a series of twenty-four successive equal monthly installments"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
Merger regulatory
"such mergers, the "Merger""
A merger is when two companies combine into a single business, with ownership and control reorganized so they operate as one entity. For investors it matters because mergers can change the value and risk of holdings—shares may be exchanged, diluted, or rise if the combined company saves costs or gains market power, and the deal often depends on regulatory approval and successful integration like two households joining resources and routines.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the Sensei Biotherapeutics (SNSE) Form 3 filed by Saira Ramasastry show?
The Form 3 shows director Saira Ramasastry holding two employee stock options on Sensei Biotherapeutics common stock. These options specify exercise prices, share amounts, and expiration dates, and were received in exchange for Faeth-related options under a February 17, 2026 merger agreement.
What are the exercise prices of the Sensei Biotherapeutics options reported on this Form 3?
The reported employee stock options have exercise prices of $5.22 and $1.16 per underlying share. These prices indicate the cost per share to exercise the options into Sensei Biotherapeutics common stock, subject to the terms and vesting schedules described in the footnotes.
When do Saira Ramasastry’s Sensei Biotherapeutics stock options expire?
The filing shows one option expiring on May 10, 2034, and another expiring on January 24, 2036. These long-dated expiration timelines outline how long the director may be able to exercise the options, subject to vesting and other applicable conditions.
Does the Form 3 for SNSE indicate any recent stock purchases or sales by Saira Ramasastry?
The Form 3 lists holdings of employee stock options rather than new open-market purchases or sales of common shares. Transaction summary data shows no buy or sell transactions, highlighting this filing as an initial reporting of derivative positions instead of trading activity.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates